DESCOVY emtricitabine 200mg/tenofovir alafenamide 25mg tablets for PrEP pre-exposure prophylaxis
January 19, 2020
Trademark Summary
The trademark application DESCOVY emtricitabine 200mg/tenofovir alafenamide 25mg tablets for PrEP pre-exposure prophylaxis was filed by Gilead Sciences Ireland UC, a corporation established under the laws of Ireland (the "Applicant"). The application was published for oppositions on February 2, 2020, and it was registered by office on May 21, 2020 without any oppositions.
The application was filed in Dutch (English was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Anti-viral pharmaceutical preparations
Pharmaceutical preparations for the treatment and prevention of infectious diseases
Pharmaceutical preparations for the treatment of immune dysfunction
Pharmaceutical preparations for the treatment and prevention of human immunodeficiency virus infection.
The mark was filed in class 44 with following description of goods:
Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, namely, pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services
Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, namely, pharmaceutical advice, medical and pharmaceutical consultation, medical advisory services, and providing medical information, consultancy and advisory services provided on-line over a computer network and the Internet
Providing medical information and advisory services regarding HIV infection.